Mylan To Pay SEC $30M For Misclassifying EpiPen

(August 8, 2019, 7:03 AM EDT) -- HERTFORDSHIRE, England — Mylan N.V. on July 29 said it has reached a $30 million agreement-in-principle to settle a U.S. Securities and Exchange Commission investigation into the misclassification of the EpiPen...
To view the full article, register now.